Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer

Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer

Background: Comprehensive biomarker testing is essential in selecting optimal treatment for patients with metastatic colorectal cancer (mCRC); however, incomplete genotyping is widespread, with most patients not receiving testing for all guideline-recommended biomarkers, in part due to reliance on b...

Full description

Bibliographic Details
Main Authors: Alba, E. (Author), Alcaide-Garcia, J. (Author), Ales, I. (Author), Álvarez, M. (Author), Benavides, M. (Author), Durán, G. (Author), Faull, I. (Author), Gil-Calle, S. (Author), Kushnir, M. (Author), Odegaard, J. (Author), Pereda, T. (Author), Reyna-Fortes, C. (Author), Robles, M. (Author), Sevilla, I. (Author), Torres, E. (Author), Wolman, R. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
biomarker
circulating tumor DNA
genomic profiling
liquid biopsy
metastatic colorectal cancer
next-generation sequencing
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items